Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Virtu Financial LLC

Virtu Financial LLC lifted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 308.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,132 shares of the biotechnology company’s stock after buying an additional 5,388 shares during the quarter. Virtu Financial LLC’s holdings in Repligen were worth $907,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Utah Retirement Systems grew its position in shares of Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 100 shares in the last quarter. State of Michigan Retirement System lifted its stake in Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $1,585,000 after purchasing an additional 100 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Repligen by 0.7% during the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock worth $1,858,000 after purchasing an additional 100 shares during the last quarter. Signaturefd LLC lifted its stake in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares during the last quarter. Finally, Commerce Bank lifted its stake in Repligen by 7.5% during the first quarter. Commerce Bank now owns 1,899 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 133 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an “overweight” rating and a $150.00 target price for the company. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Evercore ISI reduced their price objective on Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Finally, Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $169.45.

Repligen Price Performance

Repligen stock opened at $111.88 on Tuesday. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The business has a 50 day simple moving average of $122.63 and a 200-day simple moving average of $133.75. The stock has a market capitalization of $6.29 billion, a PE ratio of -447.50, a price-to-earnings-growth ratio of 2.05 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The company had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. During the same quarter last year, the company earned $0.40 EPS. Repligen’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.